Cancer charities join to prioritise interests of patients in Brexit negotiations
Tuesday 20 March 2018
Today, we’ve come together with 18 other cancer charities to publish an open letter calling on the Government to prioritise the interests of people affected by cancer in the second phase of Brexit negotiations.
As cancer charities representing patients, we believe it is vital the UK retains access to the most innovative cancer treatments and the ability to collaborate on the development of new drugs through clinical trials.
Regulatory alignment with the EU on clinical trials and drugs licensing is crucial to ensure patient safety, timely access to life-saving cancer drugs and our continued participation in clinical trials.
Our involvement in the European-wide process helps people with cancer in the UK get life-saving new drugs quickly – and we cannot afford for that to change.
The Government must send a clear message to patients that there will be no delay in access to these life-saving cancer drugs after we leave the European Union.